Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma (CAC-CBC)
Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma: Establishment of a Prospective Observational Cohort and Followed 3 Years
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The skin cancer is a major public health problem whose incidence is increasing due to the aging population. Among them, basal cell carcinoma (BCC) is a daily concern the dermatologist. The recommendation of good practice for the BCC of support has been established according to French agency methodology in 2004 : "Agence Nationale d'Accréditation et d'Evaluation en Santé" (ANAES). This classification is based on clinical and pathological use of sometimes mismatched terminology pretending to clinical reality with discrepancies between the clinical appearance and histology. On the other hand the simplified classification of recommendations has never been tested and validated on a large series of BCC. Probabilistic margins applied based on clinical assessment of clinical and pathological subtype, it seems interesting to evaluate the consistency of the initial clinical diagnosis and histological diagnosis and to explore its prognostic impact in terms of risk of recurrence.
This study could lead to improved clinical and pathological classification and allow amending the current recommendations of the surgical management of the BCC.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Armentieres, France, 59280
- Wiart (Dermatologue - Armentieres)
-
Auch, France, 32000
- Dupin (Dermatologue - Auch)
-
Bordeaux, France, 33000
- University Hospital of Bordeaux - Hospital Saint André
-
Brumath, France, 67170
- Will (Dermatologue - Brumath)
-
Evreux, France, 27000
- Ruto (Dermatologue - Evreux)
-
Hyeres, France, 83400
- Jacquet (Dermatologue - Hyeres)
-
Le Puy En Velay, France, 43000
- Tranchand (Dermatologue - Le Puy En Velay)
-
Lille, France, 51000
- Groupe Hospitalier de l'Institut Catholique de Lille
-
Marseille, France, 130005
- Bacconier (Dermatologue - Marseille)
-
Mulhouse, France, 68100
- Haberstroh (Dermatologue - Mulhouse)
-
NAY, France, 64800
- Bolzinger (Dermatologue - Nay)
-
Nice, France, 06000
- Chu De Nice
-
PAU, France, 64000
- Tanguy (Dermatologue - Pau)
-
Paris, France, 75000
- Chaussade (Dermatologue - Paris)
-
Toulouse, France, 31000
- CHU de Toulouse
-
Toulouse, France, 31000
- Bailly (Dermatologue - Toulouse)
-
Vendome, France, 41100
- Lulin (Dermatologue - Vendome)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Primitive BCC
- BCC clinically suspected or previously biopsied
- Supports conventional surgical or micrographic techniques.
- Patient able to sign a consent after reading the briefing note
Exclusion Criteria:
- Recurrent CBC
- prior medical treatment
- BCC assigned to another operator for removal
- Genodermatosis underlying (xeroderma pigmentosum - Gorlin syndrome)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
A cohort of basal cell carcinoma
A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases.
The management of the BCC will be consistent with current recommendations.
BCC recurrence and those who received prior medical treatment will be excluded.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dimension of basal cell carcinoma.
Time Frame: Day 1
|
Day 1
|
|
Number of clinical type of basal cell carcinoma (nodular, superficial or sclerodermiform)
Time Frame: Day 1
|
Day 1
|
|
Number of histological type of basal cell carcinoma (nodular, superficial, infiltrating or sclerodermiform)
Time Frame: Day 1
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of the disease according to region (head, leg, arm, eyelid, lip,...)
Time Frame: Day 1
|
Day 1
|
|
Clinical aggressiveness Score with "Agence Nationale d'Accréditation et d'Evaluation en Santé" (ANAES) criteria
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jean Michel AMICI, MD, University Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2014/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.